Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.

J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023

The company has faced thousands of lawsuits alleging its talcum powder caused users to develop ovarian cancer, although medical research indicates it is safe.

J&J To End Sales Of Baby Powder With Talc Globally Next Year

Company has faced lawsuits about its talc products but insists they are safe

Johnson & Johnson to stop making talc-based baby powder globally

Johnson & Johnson announced on Thursday that it will end global sales of talc-based baby powder and transition to an all cornstarch-based portfolio by 2023.

Johnson & Johnson to end sale of talc-based baby powder globally in 2023

The company faces about 38,000 lawsuits from consumers and their survivors claiming its talc products caused cancer due to contamination with asbestos.

J&J to stop selling controversial talc baby powder globally in 2023

Apple

Adobe

Eli Lilly

Microsoft

Ken Fisher (Trades, Portfolio), CEO and chief investment officer of Fisher Investments, disclosed in a regulatory filing that his firm's top five trades during the second quarter included boosts to its holdings in Johnson & Johnson ( JNJ , Financial), Apple Inc. ( AAPL , Financial) and Microsoft ( MSFT , Financial) and reductions to its positions in Eli Lily & Co. ( LLY , Financial) and Adobe Inc. ( ADBE , Financial).

Ken Fisher's Top 5 Trades in the 2nd Quarter

Johnson & Johnson will no longer sell its talc-based baby powder globally in 2023, the drugmaker said on Thursday, more than two years after it stopped selling the product in the United States and Canada.

J&J to stop selling talc-based baby powder globally in 2023

But making Johnson & Johnson an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of JNJ entered into oversold territory, changing hands as low as $167.41 per share.

Johnson & Johnson Is Oversold

Johnson & Johnson offers investors a combination of dividend growth and capital appreciation upside potential. The company is home to some of the best brands in the consumer health care space, a robust pharmaceutical portfolio, and an expansive slate of medical technology offerings.

Dividend Aristocrat Johnson & Johnson: One Of The Best Ideas Out There

Chevron

Mastercard

U.S. Bancorp

Visa

Following in the Oracle of Omaha's footsteps has been making investors richer for decades.

5 of the Safest Warren Buffett Stocks You Can Confidently Buy Right Now

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, at the Sheraton New York Hotel in New York. Joaquin Duato, Chief Executive Officer, and Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time). This live audio webcast will be available to investors and other interested part

Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Dick's Sporting Goods

Inflation has encouraged investors to look for solid dividend stocks to buy, and it makes sense. Strong dividends usually mean that management is taking care to generate profits.

3 Dividend Stocks to Buy to Beat Runaway Inflation

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (“the Company”) announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified. Dr. Mammen joined Johnson & Johnson in 2017 as Global Head of Janssen R&D, an

Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

Caterpillar

Pfizer

Blue-chip stocks are companies that have consistently provided quality, reliability, and the ability to operate profitably in the face of both good and bad times.

3 Blue-Chip Stocks With Rock-Solid Dividends

Intuitive Surgical

Walgreens

As a whole, healthcare has done better than the broader market this year.

2 Trends That Suggest Healthcare Stocks Can Beat the Bear Market

Bristol-Myers

These two drugmakers are outpacing the market this year.

2 Stocks That Could Lead the Market Recovery

AbbVie

The 2022 bear market might not be over, with some blue-chip economists predicting a further 18% to 43% decline before we bottom. JNJ and ABBV are two defensive healthcare dividend kings, which are up in 2022, helping investors sleep well at night in these turbulent times.

Johnson & Johnson And AbbVie: 2 Great Dividend Aristocrats For What's Coming Next

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2022 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Wednesday, September 7th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time). This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at ww

Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference

The healthcare stock has paid ever-increasing passive income to its shareholders for decades.

Is This World-Class Dividend Stock a Buy?

Digital Realty Trust

Enbridge

Altria

The US has likely entered a recession, as GDP has dropped two quarters in a row. Not all equities will be equally impacted by a recession.

5 Dependable Stocks To Hedge Against A Recession

AstraZeneca

These stocks share several things in common.

3 Stocks We Think Could Beat the Market in the Second Half of 2022

Ross Stores

These stocks both outperformed the markets during the Great Recession.

2 Growth Stocks That Could Be Good Bear Market Buys

Archer-Daniels-Midland Company

Aflac

Dominion Energy

Con Ed

Emerson Electric

FirstEnergy

Intel

Kraft Heinz

LCNB

McDonald's

Realty Income Corp

PepsiCo

SPDR Portfolio S&P 500 High Dividend ETF

Target

We received $2,818.44 in June dividend income. This was a 21.79% year over year increase. Individual dividend growth stocks paid us $1,686.78. This represented 60% of the total dividend income received. ETFs and mutual funds accounted for 40% of our total dividend income for the month.

News for Johnson & Johnson Stock (JNJ)